Retrospective observational study of disparities in biologic therapy access for inflammatory bowel disease in New Zealand (2016–2020); using official information ACT (OIA) data

Equitable access to biologic therapy for inflammatory bowel disease is an issue. All 20 district health boards were approached under the Official Information Act to provide anonymised information on the number of patients with inflammatory bowel disease who were treated with biologics between 2016 and 2020, by ethnicity. Expected numbers were calculated from population and prevalence data. The proportions of patients in various minority communities and the White New Zealand Population were compared using a z statistic. Only seven Health Boards replied and more than 1800 patients were admitted to hospital or a day case unit to initiate therapy with a biologic. The main findings were: no significant overall difference between the observed number of Maori patients who had received biologic therapy compared to expected; no difference in access to biologics in the South Asian community; in Taranaki, which treated the largest number of patients significantly fewer Maori patients were treated than would be expected ( z = −3.07, p < 0.002); and in Counties Manukau, which has a large South Asian population, significantly fewer members of the community with inflammatory bowel disease received biologic therapy than would have been expected ( z = 4.4, p < 0.00001). The implications of these findings are discussed. Inequitable access to biologic therapies means that patients with inflammatory bowel disease will have a poorer quality of life and have a greater need for surgery.

Authors

Publication Details

Journal
Medico-Legal Journal
Published
2026-11-12
DOI
https://doi.org/10.1177/00258172261477193
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Retrospective observational study of disparities in biologic therapy access for inflammatory bowel disease in New Zealand (2016–2020); using official information ACT (OIA) data

Affifa Farrukh, John Francis Mayberry
Medico-Legal Journal
Inflammatory Bowel Disease
article

Retrospective observational study of disparities in biologic therapy access for inflammatory bowel disease in New Zealand (2016–2020); using official information ACT (OIA) data

Affifa Farrukh, John Francis Mayberry
article en

Abstract

Equitable access to biologic therapy for inflammatory bowel disease is an issue. All 20 district health boards were approached under the Official Information Act to provide anonymised information on the number of patients with inflammatory bowel disease who were treated with biologics between 2016 and 2020, by ethnicity. Expected numbers were calculated from population and prevalence data. The proportions of patients in various minority communities and the White New Zealand Population were compared using a z statistic. Only seven Health Boards replied and more than 1800 patients were admitted to hospital or a day case unit to initiate therapy with a biologic. The main findings were: no significant overall difference between the observed number of Maori patients who had received biologic therapy compared to expected; no difference in access to biologics in the South Asian community; in Taranaki, which treated the largest number of patients significantly fewer Maori patients were treated than would be expected ( z = −3.07, p < 0.002); and in Counties Manukau, which has a large South Asian population, significantly fewer members of the community with inflammatory bowel disease received biologic therapy than would have been expected ( z = 4.4, p < 0.00001). The implications of these findings are discussed. Inequitable access to biologic therapies means that patients with inflammatory bowel disease will have a poorer quality of life and have a greater need for surgery.

Medico-Legal Journal
Reduced inequalities, Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon